Xendo Drug Development has been acquired by QPS Holding, LLC
July 2010 — Dutch-based Xendo Holding B.V. has successfully sold its subsidiary Xendo Drug Development B.V. to QPS Holding, LLC.
Xendo’s subsidiary Xendo Drug Development (XDD) is a full-service Contract Research Organization (CRO), in which bioanalysis, drug metabolism, clinical research, data management, biometrics and drug development consultancy services for Phase I to Phase IV clinical trials are joined. The services of XDD are focused on improving the quality and safety of drugs, and speeding up their time-to-market.
Founded in 1995, QPS has bioanalysis and DMPK facilities at its Newark, Delaware headquarters, a laboratory in Taipei, Taiwan, and a Phase 1 facility in Springfield, Missouri. QPS has been providing quality services in regulated and non-regulated bioanalysis (LC/MS/MS, immunoanalytical, and hybridization-ELISA), DMPK, protein biomarkers, pharmacogenomics and pharmacogenetics markers, and Phase 1 studies to its clients worldwide.
Since its inception in 1990, Xendo has developed itself into one of the leading Western European service providers to the global life sciences, pharmaceutical and healthcare industries. The company’s service portfolio includes contract research, technical consulting, validation and compliance, regulatory affairs, contract manufacturing and bioprocess development.
The pharmaceutical industry has recently experienced a new wave of consolidation. The big pharma companies prefer to cooperate with larger CROs that have the ability to manage large scale trials on a global basis. This has led to a consolidation trend within the CRO market as well. Xendo believed that its CRO business should participate in this consolidation trend.
Xendo found in QPS the right strategic partner. QPS provides pre-clinical and clinical research services to pharmaceutical and biotechnology clients worldwide in the areas of bioanalysis, drug metabolism and pharmacokinetics, translational medicine research, early-phase clinical research and clinical research services. The company has facilities in the United States and Taiwan. “Joining the QPS organization enables XDD to realize its ambitions for global growth. In terms of activities, size and location, QPS and XDD are a perfect fit. Our combined operations in Asia, Europe and the US position us ideally to expand our portfolios in the increasingly consolidated pharmaceutical and biotechnology sector, our primary market," said Koos Koops, CEO of Xendo.
Our role in the transaction
Oaklins' team in the Netherlands advised Xendo Holding B.V. in this transaction, working together with other Oaklins' members firms to identify more than 30 potential buyers from around the world. After an intensively managed international sale process, the Oaklins' Dutch team was able to negotiate a successful deal for the shareholders of XDD.
Talk to the deal team
Related deals
ENGIE Énergie Services has sold Majorelle to Isospace
Majorelle, a pioneer in space planning in France for 40 years, has been sold to Isospace by ENGIE Énergie Services. The transaction marks a new chapter in Majorelle’s growth, bringing together complementary expertise in workplace design, space planning and fit-out while preserving its brand, teams and market positioning. Together, Majorelle and Isospace generate more than US$45 million in revenue, primarily in the Île-de-France region. The companies operate in a commercial fit-out market undergoing significant transformation, driven by evolving workplace needs, real estate asset repositioning, regulatory requirements and environmental and socioeconomic challenges. Philippe Savajols, president of Isospace and Majorelle, aims to ensure continuity for Majorelle and its teams while developing complementary capabilities and synergies across the group, preserving both companies’ respective cultures, expertise and client relationships.
Learn moreComtax has been acquired by Ryan
Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more